Breaking News Headlines Today | Ground News

See every side of every news story

Pharmaceutical Commerce image

News from Pharmaceutical Commerce

Pharmaceutical Commerce’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

Is Pharmaceutical Commerce credible or reliable? Our Factuality score answers both of those questions. When it comes to Pharmaceutical Commerce, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about Pharmaceutical Commerce

Where is Pharmaceutical Commerce located?Pharmaceutical Commerce's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Pharmaceutical Commerce News

What to Know About the Hepatitis B Shot — and Why Trump Officials Are Targeting It

Donald Trump · United States

What to Know About the Hepatitis B Shot — and Why Trump Officials Are Targeting It

81% Center coverage: 37 sources

The U.S. government long advised that all babies be immunized against hepatitis B right after birth, but a federal vaccine advisory committee voted Dec. 5 to change that.See the Story

FDA's Drug Chief Resigns Three Weeks After Appointment — REUTERS / FES376

FDA · White Oak

FDA's Drug Chief Resigns Three Weeks After Appointment

56% Center coverage: 25 sources

Eli Lilly's Next-Gen Obesity Drug Shows Biggest Weight Loss yet in Clinical Trial

Eli Lilly's Next-Gen Obesity Drug Shows Biggest Weight Loss yet in Clinical Trial

62% Center coverage: 24 sources

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage clinical trial, the company announced.In fact, some of the participants dropped out of the trial because they were losing too much weight, the pharmaceutical company said.Retatrutide is an experimental triple agonist medication, mimicking three different gut hormones in the body GLP-1, G…See the Story

Breaking News Topics Related to Pharmaceutical Commerce